
DON’T MISS THE NEXT BIG BUYOUT — THE ARORA REPORT CELEBRATES 215 BUYOUTS
By Nigam Arora 215 Buyouts — A New Record of Success for Arora Members Avidity Biosciences (RNA) has received a buyout offer from Novartis (NVS) for approximately $12B. RNA is the 215th Arora Portfolio company to be bought out. This milestone demonstrates the strength of The Arora Report’s approach. Neuromuscular Diseases Avidity Biosciences is developing RNA-targeted therapies using its antibody-oligonucleotide conjugate platform to address serious neuromuscular diseases, including Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy. Buyout Details RNA is long from $42. The buyout offer is for $72 per share in cash, roughly a 46% premium to





